Abstract: Delivery systems and methods for delivering riboflavin (R/F) and UVA irradiation to the sclera are disclosed. The R/F is delivered and then activated with UVA irradiation through the use of LEDs or optical fibers, thereby causing cross-linking of the collagen tissue. Delivery systems include implantable structures which provide surfaces that conform to the sclera. The delivery systems include various types of structures for delivery of R/F onto the sclera surface. Additionally, the delivery systems include UVA sources which provide irradiation of R/F in sclera collagen tissue.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
April 14, 2015
Assignee:
Seros Medical, LLC
Inventors:
Mark S. Blumenkranz, Edward E. Manche, Satish V. Herekar, Donald J. Eaton
Abstract: An apparatus and a method are provided for treating a targeted area of ocular tissue in a tissue-sparing manner comprising use of two or more therapeutic modalities, including thermal radiation source (such as an CW infrared fiber laser), operative in a wavelength range that has a high absorption in water, and photochemical collagen cross-linking (CXL), together with one or more specific system improvements, such as peri-operative feedback measurements for tailoring of the therapeutic modalities, an ocular tissue surface thermal control/cooling mechanism and a source of deuterated water/riboflavin solution in a delivery system targeting ocular tissue in the presence of the ultraviolet radiation. Additional methods of rapid cross-linking (RXL), are provided that further enables cross-linking (CXL) therapy to be combined with thermal therapy.
Type:
Grant
Filed:
May 2, 2011
Date of Patent:
February 3, 2015
Assignee:
Seros Medical, LLC
Inventors:
Satish V. Herekar, Edward E. Manche, Donald J. Eaton
Abstract: Systems and methods for delivering and infusing formulations containing riboflavin or its analogues, or other ophthalmic formulations, into corneal tissue are disclosed. Systems and methods are further disclosed to cross-link the corneal tissue through exposure to UVA irradiation. The systems and methods for formulation delivery employ micro-needle array delivery devices.
Type:
Application
Filed:
February 15, 2012
Publication date:
September 20, 2012
Applicant:
Seros Medical, LLC
Inventors:
Satish V. HEREKAR, Edward E. MANCHE, Donald J. EATON
Abstract: Delivery systems and methods for delivering riboflavin (R/F) and UVA irradiation to the sclera are disclosed. The R/F is delivered and then activated with UVA irradiation through the use of LEDs or optical fibers, thereby causing cross-linking of the collagen tissue. Delivery systems include implantable structures which provide surfaces that conform to the sclera. The delivery systems include various types of structures for delivery of R/F onto the sclera surface. Additionally, the delivery systems include UVA sources which provide irradiation of R/F in sclera collagen tissue.
Type:
Application
Filed:
February 14, 2012
Publication date:
August 16, 2012
Applicant:
Seros Medical, LLC
Inventors:
Mark S. Blumenkranz, Edward E. Manche, Satish V. Herekar, Donald J. Eaton
Abstract: A solution of deuterated water containing a riboflavin-based photosensitizer is provided in order to extend life-times of UVA/Rf photo-generated intra-stromal singlet oxygen, in combination with UVA delivery profiles of pulsing, fractionation, and optionally auxiliary stromal/Rf hyper-oxygenation in order to accelerate protein cross-linking density rates in ocular tissue. A 100% deuterated water solution with 0.1% riboflavin in solution increases singlet oxygen lifetimes by at least an order of magnitude without inducing endothelial cell apoptosis, thereby also permitting use of some combination of lower percentages of deuterated water, lower concentrations of riboflavin or lower dosages of UVA on intact (un-debrided) epithelium for equivalent cross-link densities compared to current acceptable corneal cross-linking procedures.
Abstract: An apparatus and a method are provided for treating a targeted area of ocular tissue in a tissue-sparing manner comprising use of two or more therapeutic modalities, including thermal radiation source (such as an CW infrared fiber laser), operative in a wavelength range that has a high absorption in water, and photochemical collagen cross-linking (CXL), together with one or more specific system improvements, such as peri-operative feedback measurements for tailoring of the therapeutic modalities, an ocular tissue surface thermal control/cooling mechanism and a source of deuterated water/riboflavin solution in a delivery system targeting ocular tissue in the presence of the ultraviolet radiation. Additional methods of rapid cross-linking (RXL), are provided that further enables cross-linking (CXL) therapy to be combined with thermal therapy.
Type:
Application
Filed:
May 2, 2011
Publication date:
November 17, 2011
Applicant:
Seros Medical, LLC
Inventors:
Satish V. Herekar, Edward E. Manche, Donald J. Eaton
Abstract: A system for accurately delivering bilateral simultaneous equi-dosed time-fractionated pulsed UVA to irradiate a class of riboflavin/collagen mixture in the presence of oxygen for treatment of ocular tissue such as scleral and corneal tissue. The system employs ocular trial frames for mounting on the face that are fitted with 1) a nozzle for introducing Riboflavin in solution to collagen on the surface of the ocular tissue, 2) a port for introducing oxygen-rich gas to the ocular tissue, and 3) a pair of optical collimator inserts mounted in the lens holders, wherein the collimator inserts have a mask in the optical path at an aperture on focal point to control the pattern of UVA radiation at the ocular target, the collimator inserts further having optical input ports coupled to a controlled source of UVA radiation that is operative in accordance with the related inventive method.